Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
What is Cagrilintide?
Cagrilintide (also known as AM833 or NNC0174-0833) is a long-acting synthetic amylin analogue being investigated for weight management and type 2 diabetes. It works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking the natural hormone amylin that helps regulate appetite, slows gastric emptying, and promotes satiety.
When is Cagrilintide Used?
Weight Management:
- For adults with obesity (BMI ≥30 kg/m²)
- For overweight adults (BMI ≥27 kg/m²) with weight-related conditions
- Often combined with semaglutide (CagriSema) for enhanced weight loss
Type 2 Diabetes:
- To improve glycemic control alongside metformin
- To support weight loss in diabetic patients
- May help with insulin resistance
What is Cagrilintide?
Cagrilintide (also known as AM833 or NNC0174-0833) is a long-acting synthetic amylin analogue being investigated for weight management and type 2 diabetes. It works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking the natural hormone amylin that helps regulate appetite, slows gastric emptying, and promotes satiety.
When is Cagrilintide Used?
Weight Management:
- For adults with obesity (BMI ≥30 kg/m²)
- For overweight adults (BMI ≥27 kg/m²) with weight-related conditions
- Often combined with semaglutide (CagriSema) for enhanced weight loss
Type 2 Diabetes:
- To improve glycemic control alongside metformin
- To support weight loss in diabetic patients
- May help with insulin resistance
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.